Amonafide

Drug Profile

Amonafide

Alternative Names: CGX-571; FA 142; Nafidimide; NSC 308847; Quinamed

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antineoplastics; Isoquinolines; Naphthalimides; Small molecules
  • Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Endometrial cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer in USA (IV)
  • 24 Jan 2013 Discontinued - Phase-II for Prostate cancer in USA (IV)
  • 24 Jan 2013 Discontinued - Phase-II for Breast cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top